NK
NKGen Biotech, Inc. Common Stock
NKGN · OTC
$0.01 +0.00% (+$0.00)
1M +471.43%
Market Cap $1.57M
P/E Ratio -
Div. Yield -
ROE -
Piotroski F-Score Weak
3/9Valuation
91 /100
Cheap EV/EBITDA 1.85x
P/S 2.40x
P/E N/A
Growth
-
N/A EPS growth N/A
Rev. growth N/A
FCF growth N/A
Profitability
20 /100
Weak Gross margin 50.00%
Net margin 3,612.58%
Op. margin 3,682.67%
Quality
58 /100
Average ROIC 2,118.41%
ROA 148.68%
Asset turnover 0.04x
Debt
45 /100
Moderate Current ratio 0.05x
Int. coverage 3.08x
Net debt/EBITDA 1.77x
Stability
37 /100
Moderate Beta 0.72x
EPS volatility 211.35%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about NKGN
Online
About the company
NKGen Biotech, Inc. Common Stock (NKGEN) is a biotechnology company specializing in the development and research of therapeutic products utilizing natural killer (NK) cells. Their main focus is on harnessing the body's immune system to fight against cancer and other diseases.
Sector
Healthcare
Industry
Biotechnology
CEO
Paul Y. Song
Employees
26
Headquarters
Santa Ana